Skip to main content

Advertisement

Log in

Androgen Receptor-Positive Triple Negative Breast Cancer: A Unique Breast Cancer Subtype

  • Breast Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

The significance of androgen receptor (AR) expression in triple-negative breast cancer (TNBC) is unclear, and published studies so far have been inconclusive.

Methods

A tissue microarray was constructed using tissue obtained from 119 patients with primary TNBC and stained for AR expression. Other tissue types obtained included recurrent TNBC, normal breast tissue, adjacent ductal carcinoma-in situ (DCIS), lymph node (LN) and distant metastases. Positive AR expression was defined as ≥10 % nuclear staining.

Results

Epithelial tissue was present and evaluable in 94 TNBC patients with a total of 177 tissue cores. AR expression in TNBC was 22 of 94 (23 %). AR expression was higher in normal breast tissue (88 %) and adjacent DCIS (73 % overall). All LN metastases from AR-positive TNBC patients were also AR positive; in addition, no AR-negative TNBC patient had AR-positive LNs. AR expression was associated with older patient age (63 vs. 57 years, respectively, p = 0.051) and LN metastases (p = 0.033). Locoregional recurrence and overall/disease-specific survival were similar between AR-positive and AR-negative patients, although AR-positive patients had more advanced disease. On multivariate analysis, the presence of LN metastases was associated with poorer recurrence-free survival in AR-positive patients (hazard ratio, 4.34) (p = 0.031).

Conclusions

The AR is expressed in normal breast tissue, and expression decreases with advancement to DCIS and invasive cancer. AR-positive TNBC was more common in older patients and had a higher propensity for LN metastases. AR-positive TNBC may represent a breast cancer subtype with unique features that may be amenable to treatment with alternative targeted therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Tiefenbacher K, Daxenbichler G. The role of androgens in normal and malignant breast tissue. Breast Care (Basel). 2008;3:325–31.

    Article  PubMed Central  PubMed  Google Scholar 

  2. Cauley JA, Lucas FL, Kuller LH, Stone K, Browner W, Cummings SR. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group. Ann Intern Med. 1999;130(Pt 1):270–7.

    Article  CAS  PubMed  Google Scholar 

  3. Luo X, Shi YX, Li ZM, Jiang WQ. Expression and clinical significance of androgen receptor in triple negative breast cancer. Chin J Cancer. 2010;29:585–90.

    Article  CAS  PubMed  Google Scholar 

  4. Gucalp A, Traina TA. Triple-negative breast cancer: role of the androgen receptor. Cancer J. 2010;16:62–5.

    Article  CAS  PubMed  Google Scholar 

  5. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938–48.

    Article  CAS  PubMed  Google Scholar 

  6. Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM, Bhargava R. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol. 2010;23:205–12.

    Article  CAS  PubMed  Google Scholar 

  7. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007 109(1):25–32.

    Article  CAS  PubMed  Google Scholar 

  8. He J, Peng R, Yuan Z, et al. Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol. 2012;29:406–10.

    Article  CAS  PubMed  Google Scholar 

  9. Park S, Koo J, Park HS, et al. Expression of androgen receptors in primary breast cancer. Ann Oncol. 2010;21:488–92.

    Article  CAS  PubMed  Google Scholar 

  10. Hu R, Dawood S, Holmes MD, et al. Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res. 2011;17:1867–74.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Ogawa Y, Hai E, Matsumoto K, et al. Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int J Clin Oncol. 2008;13:431–5.

    Article  CAS  PubMed  Google Scholar 

  12. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750–67.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Burger HG. Androgen production in women. Fertil Steril. 2002;77:S3–5.

    Article  PubMed  Google Scholar 

  14. Veronesi U, Pizzocaro G. Breast cancer in women subsequent to cystic disease of the breast. Surg Gynecol Obstet. 1968;126:529–32.

    CAS  PubMed  Google Scholar 

  15. Wong YC, Xie B. The role of androgens in mammary carcinogenesis. Ital J Anat Embryol. 2001;106(Suppl 1):111–25.

    CAS  PubMed  Google Scholar 

  16. Hackenberg R, Schulz KD. Androgen receptor mediated growth control of breast cancer and endometrial cancer modulated by antiandrogen- and androgen-like steroids. Steroid Biochem Mol Biol. 1996;56–6:113–7.

    Article  Google Scholar 

  17. Danforth KN, Eliassen AH, Tworoger SS, et al. The association of plasma androgen levels with breast, ovarian and endometrial cancer risk factors among postmenopausal women. Int J Cancer. 2010;126:199–207.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008;14:8010–18.

    Article  CAS  PubMed  Google Scholar 

  19. Reis-Filho JS, Tutt ANJ. Triple negative tumours: a critical review. Histopathology. 2008;52:108–18.

    Article  CAS  PubMed  Google Scholar 

  20. Kanga SP, Martelb M, Harris LN. Triple negative breast cancer: current understanding of biology. Curr Opin Obstet Gynecol. 2008;20:40–6.

    Article  Google Scholar 

  21. Podoa F, Buydensb LMC, Deganic H, et al. Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol. 2010;4:2099–29.

    Google Scholar 

  22. Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ. Androgen receptors in breast cancer. Cancer. 1984;54:2436–40.

    Article  CAS  PubMed  Google Scholar 

  23. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, et al. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res. 2009;15:2472–8.

    Article  CAS  PubMed  Google Scholar 

  24. Parker RL, Huntsman DG, Lesack DW, Cupples JB, Grant DR, Akbari M, Gilks CB. Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol. 2002;117:723–8.

    Article  PubMed  Google Scholar 

  25. Park S, Koo JS, Kim MS, et al. Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. Ann Oncol. 2011;22:1755–62.

    Article  CAS  PubMed  Google Scholar 

  26. Billar JA, Dueck AC, Stucky CH, et al. Triple-negative breast cancers: unique clinical presentations and outcomes. Ann Surg Oncol. 2010;17(Suppl. 3):384–90.

    Article  PubMed  Google Scholar 

  27. Collins LC, Cole KS, Marotti JD, et al. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses’ Health Study. Mod Pathol. 2011;24:924–31.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgment

Funded in part by the Translational Genomics Research Institute (TGen) and Mayo Clinic 445 North Fifth Street, Phoenix, Arizona Collaborative Research Seed Grant Proposal (IRB 08-006579).

Disclosure

The authors declare no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Barbara A. Pockaj MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McGhan, L.J., McCullough, A.E., Protheroe, C.A. et al. Androgen Receptor-Positive Triple Negative Breast Cancer: A Unique Breast Cancer Subtype. Ann Surg Oncol 21, 361–367 (2014). https://doi.org/10.1245/s10434-013-3260-7

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-013-3260-7

Keywords

Navigation